Abstract
Background Global progress in reducing malaria has stalled since 2015. Analysis of the situation is particularly needed in Nigeria, the country with by far the largest share of the burden, where approximately a quarter of all cases in the world are estimated to occur.
Methods We analysed data from three nationwide surveys (Malaria Indicator Surveys in 2010 and 2015, and a National Demographic and Health Survey in 2018), with malaria parasite prevalence in children under five years of age determined by sampling from all 36 states of Nigeria, and blood slide microscopy performed in the same accredited laboratory for all samples. Changes over time were evaluated by calculating prevalence ratio (PR) values with 95% confidence intervals (CI) for each state, together with Mantel-Haenszel adjusted prevalence ratios (PRadj) for each of the six major geopolitical zones of the country.
Results Between 2010 and 2018 there were significant reductions in parasite prevalence in 25 states, but not in the remaining 11 states. Prevalence decreased most in southern zones of the country (South West PRadj = 0.53; South East PRadj = 0.59; South South PRadj = 0.51) and the North Central zone (PRadj = 0.36). Changes in the north were less marked, but were significant and indicated overall reductions by more than 20% (North West PRadj = 0.74; North East PRadj = 0.76). Changes in the south occurred mostly between 2010 and 2015, whereas those in the north were more gradual and most continued after 2015. Recent changes were not correlated with survey-reported variation in use of preventive measures.
Conclusion Reductions in malaria infection in children under five have occurred in most individual states in Nigeria since 2010, but substantial geographical variation in the timing and extent indicate challenges to be overcome to enable global malaria reduction.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
WO received support for the laboratory analysis of survey samples through the funding provided by DHS Program, and support from the African Centre for Drugs and Diagnostics Innovation (ANDI) of the WHO. DJC received funding from the UK Medical Research Council (grant MR/S009760/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the London School of Hygiene and Tropical Medicine
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data availability
All survey data were generated under the DHS Program (https://dhsprogram.com/), and may be accessed upon request to the UNICEF MICS team (http://mics.unicef.org/surveys).
Abbreviations
- (PR)
- Prevalence Ratio
- (CI)
- Confidence Intervals
- (PRadj)
- Mantel-Haenszel adjusted prevalence ratios
- (WHO)
- World Health Organization
- (DHS Program)
- Demographic and Health Surveys Program
- (MIS)
- Malaria Indicator Survey
- (NDHS)
- National Demographic and Health Survey
- (ANDI)
- African Network for Drugs and Diagnostics Network
- (ACT)
- artemisinin-based combination therapy
- (ITN)
- insecticide treated net
- (SMC)
- seasonal malaria chemoprevention.